Abstract
Background
High-sensitivity cardiac troponin T (hs-cTnT) in serum is a useful marker of acute myocardial injury, yet information is limited in patients with chronic obstructive pulmonary disease. We aimed to explore the association between hs-cTnT levels and cardiac and pulmonary dysfunction in patients with stable chronic obstructive pulmonary disease and at-risk individuals.
Methods
We examined community-dwelling adults with/without chronic obstructive pulmonary disease, with a life-long smoking history, current symptoms of dyspnea during exertion, prolonged coughing, and/or sputum. Serum hs-cTnT concentrations were measured, and subjects underwent pulmonary function tests, high-resolution computed tomography of the chest, an echocardiogram, and a 6-minute walking test.
Results
Eighty-six stable patients were identified (mean age 65.5 years; predicted forced expiratory volume in 1 second [FEV1% predicted] 75.0%). Their overall mean hs-cTnT level was 0.008 ng/mL. Logarithmically transformed hs-cTnT levels significantly and positively correlated with age, smoking index, serum high-sensitivity C-reactive protein levels, right ventricle systolic pressure, low attenuation area percentage, and brain natriuretic peptide levels (range r=0.231–0.534, P=0.000 to P=0.042). Further, logarithmically transformed hs-cTnT values significantly and negatively correlated with forced vital capacity, FEV1% predicted, diffusion capacity, arterial oxygen tension, and 6-minute walking distance (range r= −0.482 to −0.377, P=0.000 to P=0.002). Multivariate analyses showed that hs-cTnT values varied independently according to the following three parameters: high-sensitivity C-reactive protein levels (B=0.157, β=0.450, t=3.571, P=0.001), age (B=0.008, β=0.352, t=2.789, P=0.009), and right ventricular systolic pressure (B=0.008, β=0.280, t=2.202, P=0.035).
Conclusion
Even in patients with stable chronic obstructive pulmonary disease, the serum troponin T concentration was controlled by at least three major factors, ie, systemic inflammation, advancing age, and right cardiac overload.
Supplementary materials
Study design
The study design is shown in Figure S1. The subjects were recruited from March 2005 to December 2013 at the Respiratory Care Clinic, which is a secondary referral facility affiliated with the Nippon Medical School in Tokyo, Japan. From a total of 548 subjects, 86 who either had or were at risk of chronic obstructive pulmonary disease (COPD) were selected as the patient group, and any patients with cardiac and/or pulmonary comorbidities after various examinations were carefully excluded (details in the following section on Exclusion criteria).
Exclusion criteria
Subjects with only COPD were examined in this study, excluding any cardiac and pulmonary comorbidities. Subjects suffering from any one of these pulmonary and/or cardiovascular diseases were excluded: bronchial asthma, bronchiectasis, interstitial pneumonia, sinobronchial syndrome, active or old pulmonary tuberculosis, non-tuberculous mycobacteriosis, abnormal chest shadow suggestive of a lung tumor, resolved pneumothorax, lymphangioleiomyomatosis, lung cancer, diffuse panbronchiolitis, hypersensitivity pneumonitis, asbestosis, pulmonary hypertension, pneumonia, chronic eosinophilic pneumonia, chronic pulmonary thromboembolism, hypertension, ischemic heart disease, any type of arrhythmia, congestive heart failure, atrial septal aneurysm, ventricular septal aneurysm, hypertrophic cardiomyopathy, valvular disease, atrial septal defect, ventricular septal defect, tetralogy of Fallot, and genetic α1 anti-trypsin deficiency. Thus, careful attention was paid to exclude all these cases with cardiopulmonary comorbidities in order to focus on subjects with only COPD or those with a life-long smoking history who exhibited clinical symptoms similar to COPD, whom we considered at-risk subjects.
Pulmonary function tests
The tests were performed by well-trained technicians according to the American Thoracic Society guidelinesCitation1 using specialized equipment for lung function testing with computer processing (Chestac 55; Chest Co., Tokyo, Japan). The standards of the Japanese Respiratory SocietyCitation2 were used as the reference values for post-bronchodilator forced expiratory volume in 1 second and forced vital capacity.
High-resolution computed tomography
We performed helical high-resolution computed tomography scans at 1.25 mm collimation, 0.8 second scan time (rotation time), 120 kV, and 100–600 mA using a Light Speed Pro16 CT Scanner (GE Co., Tokyo, Japan).
Echocardiography
The same experienced echocardiographer performed the procedure on all subjects. The examination was recorded in the standard parasternal and apical views during normal breathing at end-expiration. All measurements were obtained according to the standards of the American Society of Echocardiography.Citation3 The left ventricular internal end-diastolic and end-systolic diameters were measured over five consecutive cycles. Systolic pulmonary artery pressure was calculated using the modified Bernoulli equation with an estimated right atrial pressure of 10 mmHg.
Multiple regression analysis for hs-cTnT levels (logged) in the COPD group and at-risk group
We determined whether this multivariate model for high-sensitivity cardiac troponin T (hs-cTnT) would be accurate for both a subgroup of COPD and at-risk subjects. High-sensitivity C-reactive protein and age, but not right ventricular systolic pressure, were associated with hs-cTnT using this model for these two subgroups (Tables S1 and S2).
Association between hs-cTnT levels (logged) and demographic and cardiopulmonary parameters in subjects with median or higher hs-TnT levels and in subjects with lower hs-TnT levels
The hs-cTnT level was low in the entire population. Thus, we also performed simple correlation analyses between hs-cTnT and clinical parameters (Table S3), and performed stepwise regression analysis on logged hs-cTnT values (Table S4) again in the subjects whose hs-cTnT was greater than the median (0.007). Although the population was relatively small in this analysis, we were still able to observe an association between hs-cTnT and C-reactive protein.
References
- Global Initiative for Chronic Obstructive Lung Disease Executive Committee2004 update: Workshop Report, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseaseMedical Communications Resources, Inc Updated2004 Available from: http://www.goldcopd.org/Accessed October 19, 2014
- Japanese Respiratory SocietyThe predicted values of spirometry and arterial blood gas analysis in JapaneseJ Jpn Respir Soc200139117 Japanese
- CheitlinMDArmstrongWFAurigemmaGPAmerican College of Cardiology, American Heart Association, American Society of Echocardiography. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography)Circulation200310891146116212952829
Disclosure
The authors report no conflicts of interest in this work.